553 related articles for article (PubMed ID: 30967859)
1.
Shevtsov M; Pitkin E; Ischenko A; Stangl S; Khachatryan W; Galibin O; Edmond S; Lobinger D; Multhoff G
Front Immunol; 2019; 10():454. PubMed ID: 30967859
[TBL] [Abstract][Full Text] [Related]
2. Radiochemotherapy combined with NK cell transfer followed by second-line PD-1 inhibition in a patient with NSCLC stage IIIb inducing long-term tumor control: a case study.
Kokowski K; Stangl S; Seier S; Hildebrandt M; Vaupel P; Multhoff G
Strahlenther Onkol; 2019 Apr; 195(4):352-361. PubMed ID: 30747241
[TBL] [Abstract][Full Text] [Related]
3. Control of metastasized pancreatic carcinomas in SCID/beige mice with human IL-2/TKD-activated NK cells.
Stangl S; Wortmann A; Guertler U; Multhoff G
J Immunol; 2006 May; 176(10):6270-6. PubMed ID: 16670338
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of tumor growth in mice with severe combined immunodeficiency is mediated by heat shock protein 70 (Hsp70)-peptide-activated, CD94 positive natural killer cells.
Moser C; Schmidbauer C; Gürtler U; Gross C; Gehrmann M; Thonigs G; Pfister K; Multhoff G
Cell Stress Chaperones; 2002 Oct; 7(4):365-73. PubMed ID: 12653481
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor activity of patient-derived NK cells after cell-based immunotherapy--a case report.
Milani V; Stangl S; Issels R; Gehrmann M; Wagner B; Hube K; Mayr D; Hiddemann W; Molls M; Multhoff G
J Transl Med; 2009 Jun; 7():50. PubMed ID: 19549307
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
7. Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances antitumor activity in glioblastoma treatment.
Hardcastle J; Mills L; Malo CS; Jin F; Kurokawa C; Geekiyanage H; Schroeder M; Sarkaria J; Johnson AJ; Galanis E
Neuro Oncol; 2017 Apr; 19(4):493-502. PubMed ID: 27663389
[TBL] [Abstract][Full Text] [Related]
8. Treatment of colon and lung cancer patients with ex vivo heat shock protein 70-peptide-activated, autologous natural killer cells: a clinical phase i trial.
Krause SW; Gastpar R; Andreesen R; Gross C; Ullrich H; Thonigs G; Pfister K; Multhoff G
Clin Cancer Res; 2004 Jun; 10(11):3699-707. PubMed ID: 15173076
[TBL] [Abstract][Full Text] [Related]
9. Influence of Hsp70 and HLA-E on the killing of leukemic blasts by cytokine/Hsp70 peptide-activated human natural killer (NK) cells.
Stangl S; Gross C; Pockley AG; Asea AA; Multhoff G
Cell Stress Chaperones; 2008; 13(2):221-30. PubMed ID: 18759005
[TBL] [Abstract][Full Text] [Related]
10. Adoptive transfer of human natural killer cells in mice with severe combined immunodeficiency inhibits growth of Hsp70-expressing tumors.
Multhoff G; Pfister K; Botzler C; Jordan A; Scholz R; Schmetzer H; Burgstahler R; Hiddemann W
Int J Cancer; 2000 Dec; 88(5):791-7. PubMed ID: 11072250
[TBL] [Abstract][Full Text] [Related]
11. The PD-1/B7-H1 pathway modulates the natural killer cells versus mouse glioma stem cells.
Huang BY; Zhan YP; Zong WJ; Yu CJ; Li JF; Qu YM; Han S
PLoS One; 2015; 10(8):e0134715. PubMed ID: 26266810
[TBL] [Abstract][Full Text] [Related]
12. Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade.
Fang L; Ly D; Wang SS; Lee JB; Kang H; Xu H; Yao J; Tsao MS; Liu W; Zhang L
J Exp Clin Cancer Res; 2019 Mar; 38(1):123. PubMed ID: 30857561
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model.
Mathios D; Park CK; Marcus WD; Alter S; Rhode PR; Jeng EK; Wong HC; Pardoll DM; Lim M
Int J Cancer; 2016 Jan; 138(1):187-94. PubMed ID: 26174883
[TBL] [Abstract][Full Text] [Related]
14. Adaptive NK Cell Therapy Modulated by Anti-PD-1 Antibody in Gastric Cancer Model.
Abdolahi S; Ghazvinian Z; Muhammadnejad S; Ahmadvand M; Aghdaei HA; Ebrahimi-Barough S; Ai J; Zali MR; Verdi J; Baghaei K
Front Pharmacol; 2021; 12():733075. PubMed ID: 34588986
[TBL] [Abstract][Full Text] [Related]
15. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.
Hsu J; Hodgins JJ; Marathe M; Nicolai CJ; Bourgeois-Daigneault MC; Trevino TN; Azimi CS; Scheer AK; Randolph HE; Thompson TW; Zhang L; Iannello A; Mathur N; Jardine KE; Kirn GA; Bell JC; McBurney MW; Raulet DH; Ardolino M
J Clin Invest; 2018 Oct; 128(10):4654-4668. PubMed ID: 30198904
[TBL] [Abstract][Full Text] [Related]
16. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.
Sun F; Guo ZS; Gregory AD; Shapiro SD; Xiao G; Qu Z
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461344
[TBL] [Abstract][Full Text] [Related]
17. PD-1
Trefny MP; Kaiser M; Stanczak MA; Herzig P; Savic S; Wiese M; Lardinois D; Läubli H; Uhlenbrock F; Zippelius A
Cancer Immunol Immunother; 2020 Aug; 69(8):1505-1517. PubMed ID: 32296919
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients.
Lin M; Luo H; Liang S; Chen J; Liu A; Niu L; Jiang Y
J Clin Invest; 2020 May; 130(5):2560-2569. PubMed ID: 32027620
[TBL] [Abstract][Full Text] [Related]
19. Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma.
Speranza MC; Passaro C; Ricklefs F; Kasai K; Klein SR; Nakashima H; Kaufmann JK; Ahmed AK; Nowicki MO; Obi P; Bronisz A; Aguilar-Cordova E; Aguilar LK; Guzik BW; Breakefield X; Weissleder R; Freeman GJ; Reardon DA; Wen PY; Chiocca EA; Lawler SE
Neuro Oncol; 2018 Jan; 20(2):225-235. PubMed ID: 29016938
[TBL] [Abstract][Full Text] [Related]
20. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
